Development and characterization of human monoclonal antibodies that neutralize multiple TGFβ isoforms

References

• Korpal M, Kang Y. Targeting the transforming growth factor-β signalling pathway in metastatic cancer. Eur J Cancer 2010; 46:1232–40; PMID:20307969; http://dx.doi.org/10.1016/j.ejca.2010.02.040
   PubMed Web of Science ®Google Scholar
• Miyazono K. Transforming growth factor-β signaling in epithelial-mesenchymal transition and progression of cancer. Proc Japan Acad Series B, Phys Biolog Sci 2009; 85:314–23; PMID:19838011; http://dx.doi.org/10.2183/pjab.85.314
   PubMed Web of Science ®Google Scholar
• Akhurst RJ, Hata A. Targeting the TGFbeta signalling pathway in disease. Nat Rev Drug Discov 2012; 11:790–811; PMID:23000686; http://dx.doi.org/10.1038/nrd3810
   PubMed Web of Science ®Google Scholar
• Wahl SM, Wen J, Moutsopoulos N. TGF-β: a mobile purveyor of immune privilege. Immunol Rev 2006; 213:213–27; PMID:16972906; http://dx.doi.org/10.1111/j.1600-065X.2006.00437.x
   PubMed Web of Science ®Google Scholar
• Lee Y, Awasthi A, Yosef N, Quintana FJ, Xiao S, Peters A, Wu C, Kleinewietfeld M, Kunder S, Hafler DA, et al. Induction and molecular signature of pathogenic TH17 cells. Nat Immunol 2012; 13:991–9; PMID:22961052; http://dx.doi.org/10.1038/ni.2416
   PubMed Web of Science ®Google Scholar
• van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415:530–6; PMID:11823860; http://dx.doi.org/10.1038/415530a
   PubMed Web of Science ®Google Scholar
• Massague J. TGF-β signal transduction. Annu Rev Biochem 1998; 67:753–91; PMID:9759503; http://dx.doi.org/10.1146/annurev.biochem.67.1.753
   PubMed Web of Science ®Google Scholar
• Brown PD, Wakefield LM, Levinson AD, Sporn MB. Physicochemical activation of recombinant latent transforming growth factor-β's 1, 2, and 3. Growth Factors 1990; 3:35–43; PMID:2200452; http://dx.doi.org/10.3109/08977199009037500
   PubMed Web of Science ®Google Scholar
• Schultz-Cherry S, Ribeiro S, Gentry L, Murphy-Ullrich JE. Thrombospondin binds and activates the small and large forms of latent transforming growth factor-β in a chemically defined system. J Biol Chem 1994; 269:26775–82; PMID:7929413
   PubMed Web of Science ®Google Scholar
• D'Angelo M, Billings PC, Pacifici M, Leboy PS, Kirsch T. Authentic matrix vesicles contain active metalloproteases (MMP). a role for matrix vesicle-associated MMP-13 in activation of transforming growth factor-β. J Biol Chem 2001; 276:11347–53; PMID:11145962; http://dx.doi.org/10.1074/jbc.M009725200
   PubMed Web of Science ®Google Scholar
• Derynck R, Jarrett JA, Chen EY, Eaton DH, Bell JR, Assoian RK, Roberts AB, Sporn MB, Goeddel DV. Human transforming growth factor-β complementary DNA sequence and expression in normal and transformed cells. Nature 1985; 316:701–5; PMID:3861940; http://dx.doi.org/10.1038/316701a0
   PubMed Web of Science ®Google Scholar
• Gentry LE, Lioubin MN, Purchio AF, Marquardt H. Molecular events in the processing of recombinant type 1 pre-pro-transforming growth factor β to the mature polypeptide. Mol Cell Biol 1988; 8:4162–8; PMID:3185545; http://dx.doi.org/10.1128/MCB.8.10.4162
   PubMed Web of Science ®Google Scholar
• Madisen L, Webb NR, Rose TM, Marquardt H, Ikeda T, Twardzik D, Seyedin S, Purchio AF. Transforming growth factor-β 2: cDNA cloning and sequence analysis. DNA 1988; 7:1–8; PMID:3162414; http://dx.doi.org/10.1089/dna.1988.7.1
   PubMedGoogle Scholar
• Grutter C, Wilkinson T, Turner R, Podichetty S, Finch D, McCourt M, Loning S, Jermutus L, Grutter MG. A cytokine-neutralizing antibody as a structural mimetic of 2 receptor interactions. Proc Natl Acad Sci USA 2008; 105:20251–6; PMID:19073914; http://dx.doi.org/10.1073/pnas.0807200106
   PubMed Web of Science ®Google Scholar
• Cheifetz S, Bassols A, Stanley K, Ohta M, Greenberger J, Massague J. Heterodimeric transforming growth factor β. Biological properties and interaction with three types of cell surface receptors. J Biol Chem 1988; 263:10783–9; PMID:2899081
   PubMed Web of Science ®Google Scholar
• Ehrlich M, Gutman O, Knaus P, Henis YI. Oligomeric interactions of TGF-β and BMP receptors. FEBS Lett 2012; 586:1885–96; PMID:22293501; http://dx.doi.org/10.1016/j.febslet.2012.01.040
   PubMed Web of Science ®Google Scholar
• Groppe J, Hinck CS, Samavarchi-Tehrani P, Zubieta C, Schuermann JP, Taylor AB, Schwarz PM, Wrana JL, Hinck AP. Cooperative assembly of TGF-β superfamily signaling complexes is mediated by two disparate mechanisms and distinct modes of receptor binding. Mol Cell 2008; 29:157–68; PMID:18243111; http://dx.doi.org/10.1016/j.molcel.2007.11.039
   PubMed Web of Science ®Google Scholar
• Rodriguez C, Chen F, Weinberg RA, Lodish HF. Cooperative binding of transforming growth factor (TGF)-β 2 to the types I and II TGF-β receptors. J Biol Chem 1995; 270:15919–22; PMID:7608141; http://dx.doi.org/10.1074/jbc.270.27.15919
   PubMed Web of Science ®Google Scholar
• Wrana JL, Attisano L, Wieser R, Ventura F, Massague J. Mechanism of activation of the TGF-β receptor. Nature 1994; 370:341–7; PMID:8047140; http://dx.doi.org/10.1038/370341a0
   PubMed Web of Science ®Google Scholar
• Horbelt D, Denkis A, Knaus P. A portrait of Transforming Growth Factor β superfamily signalling: Background matters. Int J Biochem Cell Biol 2012; 44:469–74; PMID:22226817; http://dx.doi.org/10.1016/j.biocel.2011.12.013
   PubMed Web of Science ®Google Scholar
• Nickel J, Sebald W, Groppe JC, Mueller TD. Intricacies of BMP receptor assembly. Cytokine Growth Factor Rev 2009; 20:367–77; PMID:19926516; http://dx.doi.org/10.1016/j.cytogfr.2009.10.022
   PubMed Web of Science ®Google Scholar
• Ehrlich M, Horbelt D, Marom B, Knaus P, Henis YI. Homomeric and heteromeric complexes among TGF-β and BMP receptors and their roles in signaling. Cell Signal 2011; 23:1424–32; PMID:21515362; http://dx.doi.org/10.1016/j.cellsig.2011.04.004
   PubMed Web of Science ®Google Scholar
• Lopez-Casillas F, Wrana JL, Massague J. Betaglycan presents ligand to the TGF β signaling receptor. Cell 1993; 73:1435–44; PMID:8391934; http://dx.doi.org/10.1016/0092-8674(93)90368-Z
   PubMed Web of Science ®Google Scholar
• Rotzer D, Roth M, Lutz M, Lindemann D, Sebald W, Knaus P. Type III TGF-β receptor-independent signalling of TGF-beta2 via TbetaRII-B, an alternatively spliced TGF-β type II receptor. EMBO J 2001; 20:480–90; PMID:11157754; http://dx.doi.org/10.1093/emboj/20.3.480
   PubMed Web of Science ®Google Scholar
• del Re E, Babitt JL, Pirani A, Schneyer AL, Lin HY. In the absence of type III receptor, the transforming growth factor (TGF)-β type II-B receptor requires the type I receptor to bind TGF-beta2. J Biol Chem 2004; 279:22765–72; PMID:14996829; http://dx.doi.org/10.1074/jbc.M401350200
   PubMed Web of Science ®Google Scholar
• Cheifetz S, Hernandez H, Laiho M, ten Dijke P, Iwata KK, Massague J. Distinct transforming growth factor-β (TGF-β) receptor subsets as determinants of cellular responsiveness to three TGF-β isoforms. J Biol Chem 1990; 265:20533–8; PMID:1700790
   PubMed Web of Science ®Google Scholar
• Dasch JR, Pace DR, Waegell W, Inenaga D, Ellingsworth L. Monoclonal antibodies recognizing transforming growth factor-β. Bioactivity neutralization and transforming growth factor β 2 affinity purification. J Immunol 1989; 142:1536–41; PMID:2537357
   PubMed Web of Science ®Google Scholar
• de Martin R, Haendler B, Hofer-Warbinek R, Gaugitsch H, Wrann M, Schlusener H, Seifert JM, Bodmer S, Fontana A, Hofer E. Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-β gene family. EMBO J 1987; 6:3673–7; PMID:3322813
   PubMed Web of Science ®Google Scholar
• ten Dijke P, Hansen P, Iwata KK, Pieler C, Foulkes JG. Identification of another member of the transforming growth factor type β gene family. Proc Natl Acad Sci USA 1988; 85:4715–9; PMID:3164476; http://dx.doi.org/10.1073/pnas.85.13.4715
   PubMed Web of Science ®Google Scholar
• Mao XW, Kettering JD, Gridley DS. Immunotherapy with low-dose interleukin-2 and anti-transforming growth factor-β antibody in a murine tumor model. Cancer Biotherapy 1994; 9:317–27; PMID:7719379; http://dx.doi.org/10.1089/cbr.1994.9.317
   PubMedGoogle Scholar
• Lucas C, Bald LN, Fendly BM, Mora-Worms M, Figari IS, Patzer EJ, Palladino MA. The autocrine production of transforming growth factor-β 1 during lymphocyte activation. A study with a monoclonal antibody-based ELISA. J Immunol 1990; 145:1415–22; PMID:2384664
   PubMed Web of Science ®Google Scholar
• Flanders KC, Roberts AB, Ling N, Fleurdelys BE, Sporn MB. Antibodies to peptide determinants in transforming growth factor β and their applications. Biochemistry 1988; 27:739–46; PMID:2450577; http://dx.doi.org/10.1021/bi00402a037
   PubMed Web of Science ®Google Scholar
• Danielpour D, Dart LL, Flanders KC, Roberts AB, Sporn MB. Immunodetection and quantitation of the two forms of transforming growth factor-β (TGF-β 1 and TGF-β 2) secreted by cells in culture. J Cell Physiol 1989; 138:79–86; PMID:2910889; http://dx.doi.org/10.1002/jcp.1041380112
   PubMed Web of Science ®Google Scholar
• Schwimmer LJ, Huang B, Giang H, Cotter RL, Chemla-Vogel DS, Dy FV, Tam EM, Zhang F, Toy P, Bohmann DJ, et al. Discovery of diverse and functional antibodies from large human repertoire antibody libraries. J Immunol Meth 2013; 391:60–71; http://dx.doi.org/10.1016/j.jim.2013.02.010
   PubMed Web of Science ®Google Scholar
• Ruegemer JJ, Ho SN, Augustine JA, Schlager JW, Bell MP, McKean DJ, Abraham RT. Regulatory effects of transforming growth factor-β on IL-2- and IL-4-dependent T cell-cycle progression. J Immunol 1990; 144:1767–76; PMID:2407783
   PubMed Web of Science ®Google Scholar
• Hoefer M, Anderer FA. Anti-(transforming growth factor β) antibodies with predefined specificity inhibit metastasis of highly tumorigenic human xenotransplants in nu/nu mice. Cancer Immunol Immunother 1995; 41:302–8; PMID:8536276; http://dx.doi.org/10.1007/BF01517218
   PubMed Web of Science ®Google Scholar
• Sengle G, Ono RN, Sasaki T, Sakai LY. Prodomains of transforming growth factor β (TGFbeta) superfamily members specify different functions: extracellular matrix interactions and growth factor bioavailability. J Biol Chem 2011; 286:5087–99; PMID:21135108; http://dx.doi.org/10.1074/jbc.M110.188615
   PubMed Web of Science ®Google Scholar
• De Crescenzo G, Pham PL, Durocher Y, Chao H, O'Connor-McCourt MD. Enhancement of the antagonistic potency of transforming growth factor-β receptor extracellular domains by coiled coil-induced homo- and heterodimerization. J Biol Chem 2004; 279:26013–8; PMID:15044491; http://dx.doi.org/10.1074/jbc.M400655200
   PubMed Web of Science ®Google Scholar
• Van Aarsen LA, Leone DR, Ho S, Dolinski BM, McCoon PE, LePage DJ, Kelly R, Heaney G, Rayhorn P, Reid C, et al. Antibody-mediated blockade of integrin α v β 6 inhibits tumor progression in vivo by a transforming growth factor-β-regulated mechanism. Cancer Res 2008; 68:561–70; PMID:18199553; http://dx.doi.org/10.1158/0008-5472.CAN-07-2307
   PubMed Web of Science ®Google Scholar
• Lonning S, Mannick J, McPherson JM. Antibody targeting of TGF-β in cancer patients. Curr Pharm Biotechnol 2011; 12:2176–89; PMID:21619535; http://dx.doi.org/10.2174/138920111798808392
   PubMed Web of Science ®Google Scholar
• Kubiczkova L, Sedlarikova L, Hajek R, Sevcikova S. TGF-β - an excellent servant but a bad master. J Trans Med 2012; 10:183; http://dx.doi.org/10.1186/1479-5876-10-183
   PubMed Web of Science ®Google Scholar
• Mittl PR, Priestle JP, Cox DA, McMaster G, Cerletti N, Grutter MG. The crystal structure of TGF-β 3 and comparison to TGF-β 2: implications for receptor binding. Protein Sci 1996; 5:1261–71; PMID:8819159; http://dx.doi.org/10.1002/pro.5560050705
   PubMed Web of Science ®Google Scholar
• Kingsley DM. The TGF-β superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev 1994; 8:133–46; PMID:8299934; http://dx.doi.org/10.1101/gad.8.2.133
   PubMed Web of Science ®Google Scholar
• Graycar JL, Miller DA, Arrick BA, Lyons RM, Moses HL, Derynck R. Human transforming growth factor-β 3: recombinant expression, purification, and biological activities in comparison with transforming growth factors-β 1 and -β 2. Mol Endocrinol 1989; 3:1977–86; PMID:2628733; http://dx.doi.org/10.1210/mend-3-12-1977
   PubMed Web of Science ®Google Scholar
• Roberts AB, Sporn MB. Differential expression of the TGF-β isoforms in embryogenesis suggests specific roles in developing and adult tissues. Mol Repro Dev 1992; 32:91–8; http://dx.doi.org/10.1002/mrd.1080320203
   PubMed Web of Science ®Google Scholar
• Gold LI, Jussila T, Fusenig NE, Stenback F. TGF-β isoforms are differentially expressed in increasing malignant grades of HaCaT keratinocytes, suggesting separate roles in skin carcinogenesis. J Pathol 2000; 190:579–88; PMID:10727984; http://dx.doi.org/10.1002/(SICI)1096-9896(200004)190:5%3c579::AID-PATH548%3e3.0.CO;2-I
   PubMed Web of Science ®Google Scholar
• Yu L, Border WA, Huang Y, Noble NA. TGF-β isoforms in renal fibrogenesis. Kidney Int 2003; 64:844–56; PMID:12911534; http://dx.doi.org/10.1046/j.1523-1755.2003.00162.x
   PubMed Web of Science ®Google Scholar
• Mead AL, Wong TT, Cordeiro MF, Anderson IK, Khaw PT. Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Investigative ophthalmol Visual Sci 2003; 44:3394–401; http://dx.doi.org/10.1167/iovs.02-0978
   PubMed Web of Science ®Google Scholar
• Trabeculectomy Study Group, CAT-152 Trabeculectomy Study. Ophthalmology 2007; 114:1950; PMID:17908596; http://dx.doi.org/10.1016/j.ophtha.2007.07.024
   Web of Science ®Google Scholar
• Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM, Silliman N, Streisand J, Powell J, Akesson A, et al. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheumatism 2007; 56:323–33; PMID:17195236; http://dx.doi.org/10.1002/art.22289
   PubMed Web of Science ®Google Scholar
• Trachtman H, Fervenza FC, Gipson DS, Heering P, Jayne DR, Peters H, Rota S, Remuzzi G, Rump LC, Sellin LK, et al. A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int 2011; 79:1236–43; PMID:21368745; http://dx.doi.org/10.1038/ki.2011.33
   PubMed Web of Science ®Google Scholar
• Morris JC, Tan AR, Olencki TE, Shapiro GI, Dezube BJ, Reiss M, Hsu FJ, Berzofsky JA, Lawrence DP. Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-β (TGFbeta) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PloS One 2014; 9:e90353; PMID:24618589; http://dx.doi.org/10.1371/journal.pone.0090353
   PubMed Web of Science ®Google Scholar
• Stevenson JP, Kindler HL, Papasavvas E, Sun J, Jacobs-Small M, Hull J, Schwed D, Ranganathan A, Newick K, Heitjan DF, et al. Immunological effects of the TGFbeta-blocking antibody GC1008 in malignant pleural mesothelioma patients. Oncoimmunology 2013; 2:e26218; PMID:24179709; http://dx.doi.org/10.4161/onci.26218
   PubMed Web of Science ®Google Scholar
• Khaw P, Grehn F, Hollo G, Overton B, Wilson R, Vogel R, Smith Z. A phase III study of subconjunctival human anti-transforming growth factor β(2) monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy. Ophthalmology 2007; 114:1822–30; PMID:17908591; http://dx.doi.org/10.1016/j.ophtha.2007.03.050
   PubMed Web of Science ®Google Scholar
• Myszka DG. Kinetic analysis of macromolecular interactions using surface plasmon resonance biosensors. Curr Opin Biotechnol 1997; 8:50–7; PMID:9013659; http://dx.doi.org/10.1016/S0958-1669(97)80157-7
   PubMed Web of Science ®Google Scholar
• Kozack RE, d'Mello MJ, Subramaniam S. Computer modeling of electrostatic steering and orientational effects in antibody-antigen association. Biophysical J 1995; 68:807–14; http://dx.doi.org/10.1016/S0006-3495(95)80257-2
   PubMed Web of Science ®Google Scholar
• Torres M, Fernandez-Fuentes N, Fiser A, Casadevall A. The immunoglobulin heavy chain constant region affects kinetic and thermodynamic parameters of antibody variable region interactions with antigen. J Biol Chem 2007; 282:13917–27; PMID:17353196; http://dx.doi.org/10.1074/jbc.M700661200
   PubMed Web of Science ®Google Scholar
• Karlsson R, Roos H, Fägerstam L, Persson B. Kinetic and Concentration Analysis Using BIA Technology. Methods 1994; 6:99–110; http://dx.doi.org/10.1006/meth.1994.1013
   Google Scholar
• De Crescenzo G, Pham PL, Durocher Y, O'Connor-McCourt MD. Transforming growth factor-β (TGF-β) binding to the extracellular domain of the type II TGF-β receptor: receptor capture on a biosensor surface using a new coiled-coil capture system demonstrates that avidity contributes significantly to high affinity binding. J Mol Biol 2003; 328:1173–83; PMID:12729750; http://dx.doi.org/10.1016/S0022-2836(03)00360-7
   PubMed Web of Science ®Google Scholar
• Myszka DG. Improving biosensor analysis. J Mol Recognition 1999; 12:279–84; http://dx.doi.org/10.1002/(SICI)1099-1352(199909/10)12:5%3c279::AID-JMR473%3e3.0.CO;2-3
   PubMed Web of Science ®Google Scholar
• Rapoza ML, Fu D, Sendak RA. Development of an in vitro potency assay for therapeutic TGFbeta antagonists: the A549 cell bioassay. J Immunol Meth 2006; 316:18–26; http://dx.doi.org/10.1016/j.jim.2006.07.009
   PubMed Web of Science ®Google Scholar
• Catriona L, Buchanan Ard, Donna KF, Celia PH, Robert GH, Lutz UJ, Steven R. Ledbetter ANTIBODIES TO TGF-β. US: Optein, Inc., Wilmington, DE (US); Genzyme Corporation, Cambridge, MA (US), 2010:43
   Google Scholar